These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19593173)

  • 21. Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: is response to treatment predictable?
    Carey PD; Lochner C; Kidd M; Van Ameringen M; Stein DJ; Denys D
    Int Clin Psychopharmacol; 2012 Nov; 27(6):321-5. PubMed ID: 22859064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical predictors of response to pharmacotherapy with selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Tükel R; Bozkurt O; Polat A; Genç A; Atli H
    Psychiatry Clin Neurosci; 2006 Aug; 60(4):404-9. PubMed ID: 16884439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors associated with improved cognitive-behavioral therapy outcome in pediatric obsessive-compulsive disorder.
    Torp NC; Dahl K; Skarphedinsson G; Compton S; Thomsen PH; Weidle B; Hybel K; Valderhaug R; Melin K; Nissen JB; Ivarsson T
    J Am Acad Child Adolesc Psychiatry; 2015 Mar; 54(3):200-207.e1. PubMed ID: 25721185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients.
    Buchsbaum MS; Hollander E; Pallanti S; Baldini Rossi N; Platholi J; Newmark R; Bloom R; Sood E
    Neuropsychobiology; 2006; 53(3):157-68. PubMed ID: 16707915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases.
    Sun TF; Lin PY; Wu CK
    Chang Gung Med J; 2001 Sep; 24(9):587-92. PubMed ID: 11725630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computational model of obsessive-compulsive disorder: examination of etiologic hypothesis and treatment strategies.
    Ownby RL
    Depress Anxiety; 1998; 8(3):91-103. PubMed ID: 9836060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of trauma and post-traumatic stress disorder on the treatment response of patients with obsessive-compulsive disorder.
    Shavitt RG; Valério C; Fossaluza V; da Silva EM; Cordeiro Q; Diniz JB; Belotto-Silva C; Cordioli AV; Mari J; Miguel EC
    Eur Arch Psychiatry Clin Neurosci; 2010 Mar; 260(2):91-9. PubMed ID: 20077119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of head-to-head randomized controlled trials.
    Romanelli RJ; Wu FM; Gamba R; Mojtabai R; Segal JB
    Depress Anxiety; 2014 Aug; 31(8):641-52. PubMed ID: 24390912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study.
    Selvi Y; Atli A; Aydin A; Besiroglu L; Ozdemir P; Ozdemir O
    Hum Psychopharmacol; 2011 Jan; 26(1):51-7. PubMed ID: 21308781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India.
    Hegde A; Kalyani BG; Arumugham SS; Narayanaswamy JC; Math SB; Reddy YC
    J Clin Psychopharmacol; 2016 Aug; 36(4):381-4. PubMed ID: 27219093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment strategies for chronic and refractory obsessive-compulsive disorder.
    Rasmussen SA; Eisen JL
    J Clin Psychiatry; 1997; 58 Suppl 13():9-13. PubMed ID: 9402914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
    Nakamae T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.
    Simpson HB; Gorfinkle KS; Liebowitz MR
    J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurobiological model of obsessive-compulsive disorder: evidence from recent neuropsychological and neuroimaging findings.
    Nakao T; Okada K; Kanba S
    Psychiatry Clin Neurosci; 2014 Aug; 68(8):587-605. PubMed ID: 24762196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial.
    Pediatric OCD Treatment Study (POTS) Team
    JAMA; 2004 Oct; 292(16):1969-76. PubMed ID: 15507582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hoarding in obsessive-compulsive disorder and related disorders: a preliminary report of 15 cases.
    Seedat S; Stein DJ
    Psychiatry Clin Neurosci; 2002 Feb; 56(1):17-23. PubMed ID: 11929567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors and moderators of treatment outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I).
    Garcia AM; Sapyta JJ; Moore PS; Freeman JB; Franklin ME; March JS; Foa EB
    J Am Acad Child Adolesc Psychiatry; 2010 Oct; 49(10):1024-33; quiz 1086. PubMed ID: 20855047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multidimensional model of obsessive-compulsive disorder.
    Mataix-Cols D; Rosario-Campos MC; Leckman JF
    Am J Psychiatry; 2005 Feb; 162(2):228-38. PubMed ID: 15677583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels.
    Yoshimura R; Kaneko S; Shinkai K; Nakamura J
    Psychiatry Clin Neurosci; 2006 Jun; 60(3):389-93. PubMed ID: 16732759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.